Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study

Seo, Kwang Il; Yun, Byung Chul; Li, Weiquan; Lee, Sang Uk; Han, Byung Hoon; Park, Eun Taek

doi:10.3350/cmh.2016.0052

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For many years, IFN-based therapy, despite having frequent side effects, poor tolerability, suboptimal efficacy and prolonged treatment course, was recommended as the standard treatment for HCV infection[ 134 , 135 ]. Introduction of IFN-free DAAs has solved most of these problems in the treatment course of HCV infection.…”

Section: Remaining Challenges To Eliminating Hcv Infectionmentioning

confidence: 99%

“…Introduction of IFN-free DAAs has solved most of these problems in the treatment course of HCV infection. Switch the HCV treatment regimens from IFN-based therapy to DAA therapy is a desirable approach, yet encounter practical barriers such as high price and the restricted accessibility of DAAs[ 135 - 138 ]. Most of the time, the cost of antivirals rather than their effectiveness is the main driver in the treatment decisions.…”

Section: Remaining Challenges To Eliminating Hcv Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Taherkhani¹,

Farshadpour²

2017

WJH

View full text Add to dashboard Cite

Today, with the introduction of interferon-free direct-acting antivirals and outstanding progresses in the prevention, diagnosis and treatment of hepatitis C virus (HCV) infection, the elimination of HCV infection seems more achievable. A further challenge is continued transmission of HCV infection in high-risk population specially injecting drug users (IDUs) as the major reservoir of HCV infection. Considering the fact that most of these infections remain undiagnosed, unidentified HCV-infected IDUs are potential sources for the rapid spread of HCV in the community. The continuous increase in the number of IDUs along with the rising prevalence of HCV infection among young IDUs is harbinger of a forthcoming public health dilemma, presenting a serious challenge to control transmission of HCV infection. Even the changes in HCV genotype distribution attributed to injecting drug use confirm this issue. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients through risk-based screening to mitigate the risk of HCV transmission in the IDUs community and, consequently, in the society. Meanwhile, raising general awareness of HCV infection, diagnosis and treatment through public education should be the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has been lack of awareness among young drug takers. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and public education should be considered as the top priorities of any health policy decision to eliminate HCV infection.

show abstract

Section: Remaining Challenges To Eliminating Hcv Infectionmentioning

confidence: 99%

Section: Remaining Challenges To Eliminating Hcv Infectionmentioning

confidence: 99%

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Taherkhani¹,

Farshadpour²

2017

WJH

View full text Add to dashboard Cite

show abstract

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Sølund

Hallager

Pedersen

et al. 2018

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?

Smirne,

Crobu,

Landi

et al. 2024

Viruses

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics. Despite these advancements, recent studies have reported that even after sustained virologic response (SVR), individuals with advanced liver disease/cirrhosis at the time of DAA treatment may still face risks of HCC occurrence or recurrence. Based on this premise, this review tries to shed light on the multiple mechanisms that establish a tumorigenic environment, first, during chronic HCV infection and then, after eventual viral eradication by DAAs. Furthermore, it reviews evidence reported by recent observational studies stating that the use of DAAs is not associated with an increased risk of HCC development but rather, with a significantly lower chance of liver cancer compared with DAA-untreated patients. In addition, it seeks to provide some practical guidance for clinicians, helping them to manage HCC surveillance of patients who have achieved SVR with DAAs.

show abstract

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study

Cited by 4 publications

References 17 publications

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?

Contact Info

Product

Resources

About